CURRICULUM VITAE ET STUDIORUM
PROF. MARTA PALMIERI

ACADEMIC POSITIONS

January 2005 to date
Full Professor of Biochemistry (BIO/10 Biochimica) at the University of Verona.
February 2003 – December 2004
Associate Professor of Biochemistry (BIO/10 Biochimica) at the University of Verona, Faculty of Exercise Sciences.
November 1992 – January 2003
Associate Professor of Propaedeutic Biochemistry (SSD E05A, changed in SSD BIO/10) at the University of Verona, Faculty of Medicine.
December 1988 - October 1992
Research Associate of Biochemistry at the University of Verona, Faculty of Medicine.
August 1980 - November 1988
Research Associate of Biochemistry at the University of Naples, Faculty of Sciences.

INTERNATIONAL RESEARCH EXPERIENCE

August 1976
"Visiting researcher", Institute of Molecular Biology I. University of Zurich (Dir. Prof. Charles Weissmann).
January 1978 - December 1979
Post-doctoral research fellow, Institute of Molecular Biology I. University of Zurich (Dir. Prof. Charles Weissmann).
July 1985 – October 1988
Post-doctoral research fellow ("Fondation de France" and CEE), Institut de Recherches Scientifiques sur le Cancer, Villejuif, France (Dir. Dr. Ion Gresser).
March 1996 – May 1996
Post-doctoral research fellow (CNR), Institut de Recherches Scientifiques sur le Cancer, Villejuif, France (Dir. Dr. Ion Gresser).

SCIENTIFIC RESPONSIBLE OF RESEARCH PROJECTS

CNR
90.01301.CT14 – Study of the nucleotide sequences of the IL-6 promoter gene that bind in vivo gene expression regulatory proteins.
91.02483.CT14 – Study of the nucleotide sequences of the IL-6 promoter gene that bind in vivo gene expression regulatory proteins.
92.02266.CT14 – Study of the nucleotide sequences of the IL-6 promoter gene that bind in vivo gene expression regulatory proteins.
93.01349.CT14 – Regulation of IL-6 gene expression in human cell lines.
94.00376.CT14 – Regulation of IL-6 gene expression in human cell lines.

CEE
SC1*-CT91-0745 (TSTS) – Regulation of the expression of the genes of interferon and other cytokines in normal and deseased tissues (Coordinator o the project: Dr Michael Tovey, CNRS, Laboratoire d'Oncologie Virale – UPR 274, Villejuif, France)

PRIN Bando 1997

Molecular mechanisms of interleuchin-6 gene regulation. (Scientific Responsible of the Research Unit)

FONDAZIONE CARIVERONA 2004
In vitro and in vivo studies on new chemotherapeutic strategies for pancreatic adenocarcinoma: identification of the involved molecular mechanisms. (Scientific Coordinator of the Project)

AIRC REGIONAL RESEARCH PROGRAM 2008
Tumor microenvironment and tumor spread in gastrointestinal cancers. (Scientific Responsible of the Research Unit)

PRIN Bando 2009
New experimental strategies for sensitizing human pancreatic adenocarcinoma cells to standard chemotherapy. (Scientific Responsible of the Research Unit)

MAJOR SCIENTIFIC ACCOMPLISHMENT IN CANCER FIELD

1) Analyses of epigenetic modifications on cancer-related genes. These studies demonstrated the ability of histone deacetylase inhibitors to inhibit pancreatic adenocarcinoma cell proliferation in vitro and in mice models.
2) Analyses of the inhibition of pancreatic cancer cell proliferation by gemcitabine (GEM) associated with different compounds. These studies demonstrated that GEM in association with disulfiram, a drug already used in clinics for other diseases, or cannabinoids synergistically inhibits GEM-resistant pancreatic adenocarcinoma cell proliferation.
3) Analyses of the redox status and of the metabolism in pancreatic adenocarcinoma cell lines. These studies demonstrated that cells with lower basal ROS are more resistant to GEM compared to cells with higher ROS, and the oxidative stress is a crucial mechanism for the growth inhibitory effect of GEM in combination with other drugs. Furthermore, these studies showed that cannabinoids are able to inhibit energetic metabolism and to induce AMPK-dependent autophagy.
4) Analyses of the antiproliferative activity of drug containing nanovectors. These studies demonstrated that pancreatic adenocarcinoma cells expressing high levels of CD44, a typical cancer stem cell (CSC) marker, are efficiently targeted, both in vitro and in vivo, by hyaluronic acid-coated liposomes containing a lipophilic derivative of GEM.
5) Isolation and characterization of CSCs from several PDAC cell lines. These studies demonstrated that these CSCs are differentially resistant to various anticancer agents and possess higher tumorigenic and metastatic activity compared to parental cells.

FURTHER INFORMATION

- Invited speaker at national and international meetings and workshops.
- Peer Reviewer of several scientific journals.
- Coordinator of the PhD Course in Biosciences (2011-2015 University of Verona).
- Coordinator of the Section of Biological Chemistry at the Department of Neurological, Biomedical and Movement Sciences (from 2011).

PUBLICATIONS

Dalla Pozza E, Forciniti S, **Palmieri M**, Dando I. (2017)
Secreted molecules inducing epithelial-to-mesenchymal transition in cancer development. *Semin Cell Dev Biol.* 2017 Jun 30. pii: S1084-9521(16)30486-4. doi: 10.1016/j.semcdb.2017.06.027.

Brandi J, Dando I, Pozza ED, Biondani G, Jenkins R, Elliott V, Park K, Fanelli G, Zolla L, Costello E, Scarpa A, Cecconi D, **Palmieri M**. (2017)
Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways.
J Proteomics. 2017 Jan 6;150:310-322. doi: 10.1016/j.jprot.2016.10.002.

Cordani M, Oppici E, Dando I, Butturini E, Dalla Pozza E, Nadal-Serrano M, Oliver J, Roca P, Mariotto S, Cellini B, Blandino G, **Palmieri M**, Di Agostino S, Donadelli M. (2016)
Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition.
Mol Oncol. 2016 Apr 12. pii: S1574-7891(16)30016-3. doi: 10.1016/j.molonc.2016.04.001.

Brandi J, Dalla Pozza E, Dando I, Biondani G, Robotti E, Jenkins R, Elliott V, Park K, Marengo E, Costello E, Scarpa A, **Palmieri M***, Cecconi D. (2016)
Secretome protein signature of human pancreatic cancer stem-like cells.
J Proteomics. 2016 Mar 16;136:1-12. doi: 10.1016/j.jprot.2016.01.017. Epub 2016 Feb 2.
***corresponding author**

Klionsky DJ et al. (2016)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Autophagy 12, 1-222.

Dando I, Dalla Pozza E, Biondani G, Cordani M, **Palmieri M***, Donadelli M. (2015)
The metabolic landscape of cancer stem cells.
IUBMB Life doi: 10.1002/iub.1426.

Dando I, Cordani M, Dalla Pozza E, Biondani G, Donadelli M, **Palmieri M**. (2015)
Antioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem Cells.
Oxid Med Cell Longev. doi: 10.1155/2015/425708.

Donadelli M, Dando I, Dalla Pozza E, **Palmieri M**. (2015)
Mitochondrial uncoupling protein 2 and pancreatic cancer: a new potential target therapy.
World J Gastroenterol. 2015; 21(11):3232-8. doi: 10.3748/wjg.v21.i11.3232.

Dalla Pozza E, Dando I, Biondani G, Brandi J, Costanzo C, Zoratti E, Fassan M, Boschi F, Melisi D, Cecconi D, Scupoli MT, Scarpa A, **Palmieri M**. (2015)
Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi-directionally convert into cancer stem cells.
Int J Oncol. 46(3):1099-108. doi: 10.3892/ijo.2014.2796.

Donadelli M, Dando I, Fiorini C, **Palmieri M**. (2014)
Regulation of miR-23b expression and its dual role on ROS production and tumour development.
Cancer Lett. 349(2):107-13. doi: 10.1016/j.canlet.2014.04.012.

Donadelli M., Dando I., Fiorini C. and **Palmieri M.** (2014)
UCP2, a mitochondrial protein regulated at multiple levels.
Cell Mol Life Sci. DOI 10.1007/s00018-013-1407-0

Donadelli M. and **Palmieri M.** (2013)
Roles for microRNA 23b in regulating autophagy and development of pancreatic adenocarcinoma.
Gastroenterology 145, 936-938.

Arpicco S., Lerda C., Dalla Pozza E., Costanzo C., Tsapis N., Stella B., Donadelli M., Dando I., Fattal E., Cattel L. and **Palmieri M.** (2013)
Hyaluronic acid-coated liposomes for active targeting of gemcitabine.
Eur J Pharm Biopharm. 85, 373-380.

Dando I., Donadelli M., Costanzo C., Dalla Pozza E., D'Alessandro A., Zolla L. and **Palmieri M.** (2013)
Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells.
Cell Death and Disease 4:e664. doi: 10.1038/cddis.2013.151.

Brandi J., Dando I., **Palmieri M.**, Donadelli M. and Cecconi D. (2013)
Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists.
Electrophoresis 34, 1359-1368.

Dalla Pozza E., Lerda C., Costanzo C., Donadelli M., Dando I., Zoratti E., Scupoli M.T., Beghelli S., Scarpa A., Fattal E., Arpicco S. and **Palmieri M.** (2013)
Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
Biochim Biophys Acta Biomembranes 1828, 1396-1404.

Dando I., Fiorini C., Dalla Pozza E., Padroni C., Costanzo C., **Palmieri M.** and Donadelli M. (2013)
UCP2 inhibition triggers ROS-dependent nuclear translocation of GAPDH and autophagic cell death in pancreatic adenocarcinoma cells.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1833, 672-679.

Fiorini C., Menegazzi M., Padroni C., Dando I., Dalla Pozza E., Gregorelli A., Costanzo C., **Palmieri M.** and Donadelli M. (2013)
Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis.
Apoptosis 18, 337-346.

Rosati A., Bersani S., Tavano F., Dalla Pozza E., **Palmieri M.**, De Laurenzi V., Franco R., Scognamiglio G., Palaia R., Fontana A., Di Sebastiano P., Donadelli M., Dando I., Medema J.P., Dijik F., Welling L., Di Mola F., Pezzilli R., Turco M.C. and Scarpa A. (2012)
Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival.
The American Journal of Pathology 181, 1524-15291833, 672-679.

Dalla Pozza E., Fiorini C., Dando I., Menegazzi M., Sgarbossa A., Costanzo C., **Palmieri M.** and Donadelli M. (2012)
Role of mitochondrial uncopling protein 2 in cancer cell resistance to gemcitabine.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1823, 1856-1863.

Donadelli M., Dando I., Zaniboni T., Costanzo C., Dalla Pozza E., Scupoli M.T., Scarpa A., Zappavigna S., Marra M., Abbruzzese A., Bifulco M., Caraglia M. and **Palmieri M.** (2011)
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS mediated mechanism.
Cell Death and Disease 2, e152; doi:10.1038/cddis.2011.36

Dalla Pozza E., Donadelli M., Costanzo C., Zaniboni T., Dando I., Franchini M., Arpicco S., Scarpa A. and **Palmieri M.** (2011)
Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives.
Free Radic Biol Med 50, 926-933.

Cecconi D., **Palmieri M.** and Donadelli M. (2011)
Proteomics in pancreatic cancer research.
Proteomics 11, 816-828.

Dandrea M., Donadelli M., Costanzo C., Scarpa A. and **Palmieri M.** (2009)
MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines.
Nucleic Acids Research 37, 6681-6690.

Cecconi D., Donadelli M., Dalla Pozza E., Rinalducci S., Zolla L., Scapoli M.T., Rigetti P.G., Scarpa A. and **Palmieri M.** (2009)
Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study.
Proteomics 9, 1952-1966.

Donadelli M., Dalla Pozza E., Scupoli M.T., Costanzo C., Scarpa A. and **Palmieri M.** (2009)
Intracellular zinc increase inhibits $p53^{-/-}$ pancreatic adenocarcinoma cell growth by ROS/AIF-mediated apoptosis.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1793, 273-280.

Gaviraghi M., Caricasole A., Costanzo C., Diamanti D., Dandrea M., Donaldelli M., Scarpa A. and **Palmieri M.** (2008)
Identification of a candidate alternative promoter region of the human Bcl2L11 (Bim)gene.
BMC Molecular Biology 9, 56-71.

Scupoli M.T., Donadelli M., Cioffi F., Rossi M., Perbellini O., Malpeli G., Corbioli S., Vinante F., Krampera M., **Palmieri M.**, Scarpa A., Ariola C., Foà R., Pizzolo G. (2008)
Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kB and JNK/AP-1 pathways.
Haematologica 93, 524-532.

Donadelli M., Dalla Pozza E., Costanzo C., Scupoli M.T., Scarpa A., **Palmieri M.** (2008)
Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes.
J. Cell. Biochem 104, 202-212.

Donadelli M., Costanzo C., Beghelli S., Scupoli M.T., Dandrea M., Bonora A., Piacentini P., Budillon A.,
Caraglia M., Scarpa A., **Palmieri M**. (2007)
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1773, 1095-1106.

Cecconi D., Donadelli M., Rinalducci S., Zolla L., Scapoli M.T., Scarpa A., **Palmieri M.*** and Rigetti P.G. (2007)

Proteomic analysis of pancreatic endocrine tumour cell lines treated with the histone deacetylase inhibitor trichostatin A.
Proteomics 7, 1644-1653.
***corresponding author**

Lallemand C., Blanchard B., **Palmieri M.**, Lebon P., May E. and Tovey M.G. (2007)
Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3and CREB.
Oncogene 26, 328-38.

Donadelli M., Dalla Pozza E., Costanzo C., Scupoli M.T., Piacentini P., Scarpa A., **Palmieri M**. (2006)
Increased stability of P21(WAF1/CIP1) mRNA is required for ROS/ERK-dependent pancreatic adenocarcinoma cell growth inhibition by pyrrolidine dithiocarbamate.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1763, 917-926.

Piacentini P., Donadelli M., Costanzo C., Moore P. S., **Palmieri M.***, Scarpa A. (2006)
Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.
Virchows Arch. 448, 797-804.
***corresponding author**

Cecconi D., Donadelli M., Scarpa A., Milli A., **Palmieri M.**, Hamdan M., Areces L. B., Rappsilber J., Righetti P. G. (2005)
Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A.
J Proteome Res. 4, 1909-1916.

Missiaglia E., Donadelli M., **Palmieri M.**, Crnogorac-Jurcevic T., Scarpa A., Lemoine N. R. (2005)
Growth delay of pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway.
Oncogene 24, 199-211.

Moore P. S., Barbi S., Donadelli M., Costanzo C., Bassi C, **Palmieri M.** and Scarpa A. (2004)
Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1693, 167-176.

Faggioli L., Costanzo C., Donadelli M. and **Palmieri M.** (2004)
Activation of the interleukin-6 promoter by a dominant negative mutant of c-Jun.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1692, 17-24.

Cecconi D., Astner H., Donadelli M., **Palmieri M.**, Missiaglia E., Hamdan M., Scarpa A. and Righetti P. G (2003)
Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2'-deoxycytidine.
Electrophoresis 24, 4291-4303.

Donadelli M., Costanzo C., Faggioli L., Scupoli M. T., Moore P., Bassi C., Scarpa A. and **Palmieri M.** (2003)
Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells.

Molecular Carcinogenesis **38,** 59-69.

Cecconi D., Scarpa A., Donadelli M., **Palmieri M.,** Hamdan M., Aster H. and Righetti, P. G. (2003)
Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A.
Electrophoresis **24,** 1871-1878.

Lallemand C., **Palmieri M.**, Blanchard B., Meritet J-F. and Tovey M. G. (2002)
GAAP-1: a transcriptional activator of p53 and IRF-1 possesses pro-apoptotic activity.
EMBO reports **3,** 153-158.

Armenante F., Merola M., Furia A., Tovey M. and **Palmieri M.** (1999)
Interleukin-6 repression is associated with a distinctive chromatin structure of the gene.
Nucleic Acids Research **27,** 4483-4490.

Costanzo C., Piacentini G., Vicentini L., Armenante F., Mazzi P., Savio C., Faggioli L., Boner A. and **Palmieri M.** (1999)
Cell specific differences in the regulation of the IL-6 gene expression by PMA.
Biochim. Biophys. Res. Comm. **260,** 577-581.

Palmieri M., Sasso M. P., Monese R., Merola M., Faggioli L., Tovey M. and Furia, A. (1999)
Interaction of the nuclear protein CBF1 with the kB site of the IL-6 gene promoter.
Nucleic Acids Res. **27,** 2785-2791.

Armenante F., Merola M., Furia A. and **Palmieri M.** (1999)
Repression of the IL-6 gene is associated with hypermethylation.
Biochem. Biophys. Res. Comm. **258,** 644-647.

Sasso M. P., Lombardi M., Confalone E., Carsana A., **Palmieri M.** and Furia A. (1999)
The differential pattern of tissue specific expression of ruminant pancreatic type ribonucleases may help to understand the evolutionary history of their genes.
Gene **227,** 205-212.

Cavallini G., Bovo P., Bianchini E., Carsana A., Costanzo C., Merola M., Sgarbi D., Frulloni L., Di Francesco V., Libonati M. and **Palmieri M.** (1998)
Lithostathine messenger RNA expression in different types of chronic pancreatitis.
Mol. Cell. Biochem. **185,** 147-152.

Faggioli L., Merola M., Hiscott J., Furia A., Monese R., Tovey M. and **Palmieri M.**(1997)
Molecular mechanisms regulating induction of interleukin-6 gene transcription by interferon-g.
Eur. J. Immunol. **27,** 3022-3030.

Faggioli L., Costanzo C., Merola M., Furia A. and **Palmieri M.** (1997)
Protein synthesis inhibitors cycloheximide and anisomycin induce interleukin-6 gene expression and activate transcription factor NF-kB.
Biochem. Biophys. Res. Comm. **233,** 507-513.

Faggioli L., Costanzo C., Merola M., Bianchini E., Furia A., Carsana A. and **Palmieri M.** (1996)
Nuclear factor kB, nuclear factor interleukin-6 (NFIL6 or C/EBPb) and nuclear factor interleukin-6b (NFIL6b or C/EBPd) are not sufficient to activate the endogenous interleukin-6 gene in the

human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6 expressing human breast carcinoma cell line.
Eur J Biochem, **239,** 624-631.

Confalone E., Sasso M.P., Carsana A., Beintema J.J., Vento T., **Palmieri M.** and Furia A. (1995)
Molecular evolution of genes encoding ribonucleases in ruminant species.
J Mol Evol, **41,** 850-858.

Breukelman H.J., Beintema J.J., Confalone E., Costanzo C., Sasso M.P., Carsana A., **Palmieri M.** and Furia A. (1993)
Sequences related to the ox pancreatic ribonuclease coding region in the genomic DNA of mammalian species.
J Mol Evol **37,** 29-35.

Carsana A., Merola M., Costanzo C., Maffei L., Lievens P.M.J., Furia A. and **Palmieri M.** (1992)
Protein-DNA interaction in the 5'-flanking region of the bovine pancreatic ribonuclease gene.
Biochim Biophys Acta **1171,** 147-152.

Grassi-Zucconi G., Cosi C., **Palmieri M.**, Furia A., Bassetti M.A. and Carsana A. (1992)
A pancreatic-like ribonucleaseis synthesized in rat brain.
Molecular Brain Research **14,** 1-6.

Sasso M.P., Carsana A., Confalone E., Cosi C., Sorrentino S., Viola M., **Palmieri M.,** Russo E. and Furia A. (1991)
Molecular cloning of the gene encoding the bovine brain ribonuclease and its expression in different regions of the brain.
Nucleic Acids Research **19,** 6469-6474.

Palmieri M. and Tovey M.G. (1990)
Genomic footprinting: detection of putative regulatory proteins in the promoter region of the interferon a-1 gene in normal human tissues.
Mol Cell Biol **10,** 2554-2561.

Carsana A., Confalone E., **Palmieri M.**, Libonati M. and Furia A. (1988)
Structure of the bovine pancreatic ribonuclease gene: the unique intervening sequence in the 5' untraslated region contains a promoter-like element.
Nucleic Acid Research **16,** 5491-5502.

Piccoli R., Pasanisi A., Carsana A., **Palmieri M.** and D'Alessio G. (1988)
Expression of opioid genes in bovine seminal vesicles.
Eur J Biochem **172,** 53-58.

Palmieri M., Carsana A., Furia A. and Libonati M. (1985)
Sequence analysis of a cloned cDNA coding for bovine seminal ribonuclease.
Eur J Biochem **152,** 275-277.

Carsana A., Furia A., Calabria R. and **Palmieri M.** (1985)
In vitro synthesis of pig pancreas ribonuclease.
Biochim Biophys Acta **825,** 299-302.

Furia A., **Palmieri M.** and Libonati M. (1983)

Bovine seminal ribonuclease precursor synthesized 'in vitro'.
Biochim Biophys Acta **741,** 303-307. **4.374**

Taniguchi T., **Palmieri M.** and Weissmann C. (1978)
Qß DNA-containing hybrid plasmids giving rise to Qß phage formation in the bacterial host.
Nature **274,** 223-228.

Taniguchi T, Palmieri M, Weissmann C. (1978)
A Qbeta DNA-containing hybrid plasmid giving rise to Qbeta phage formation in the bacterial host [proceedings].
Ann Microbiol (Paris). Nov-Dec;129 B(4):535-6.

Libonati M. and **Palmieri M.** (1978)
How much is secondary structure responsible for resistence of double-stranded RNA to pancreatic ribonuclease A ?
Biochim Biophys Acta **518,** 277-289.

Palmieri M. and Libonati M. (1977)
Differential, structure-dependent susceptibily of poli(A) and RNA to monomeric and dimeric pancreatic ribonuclease A.
Biochim Biophys Acta **474,** 456-466.

Parente A., **Palmieri M.**, De Prisco R. e Libonati M. (1977)
Correlazione fra basicità delle molecole di ribonucleasi e degradazione di RNA a doppia elica: un ulteriore contributo.
Boll Soc Ital Biol Sper **53,** 466-470.

Sorrentino S., **Palmieri M.** e Libonati M. (1977)
Influenza della forza ionica sull'attivita' della RNAasi A monomerica e dimerica sul poli(A).
Boll Soc Ital Biol Sper **53,** 461-465.

Palmieri M. e Libonati M. (1976)
Suscettibilità differenziale, struttura-dipendente, del poli(A) a RNAasi pancreatica e RNAasi BS1.
Boll Soc Ital Biol Sper **52,** 80-84.

Palmieri M. e Libonati M. (1976)
Meccanismo endonucleolitico della degradazione di RNA a doppia elica ad opera di RNAasi BS1 e di aggregati di RNAasi A.
Boll Soc Ital Biol Sper **52,** 74-79.